Vertex Beats Expectations in 2019 Vertex (VRTX) reported fourth-quarter and full-year 2019 financial results yesterday. The results beat analysts’ expectations about the last quarter and the whole year 2019. In the same report the firm’s full-year financial guidance promises a thrilling future for Vertex. The report indicated that the total GAAP and Non . . . This content is for paid subscribers. Please click here to …

Regenxbio, Moderna and Others Regenxbio (RGNX) announced several poster presentations including interim data from its Phase I/II trial of RGX-121 for the treatment of Mucopolysaccharidosis Type II (MPS II

Time to Remember Compugen The time has ripened for our readers and biotech investors to remember what we posted in the past years about Compugen (CGEN). The importance of the reminder is that the firm has taken a long time to bring its target discoveries and its targeted treatments into clinical trials whose preliminary results have demonstrated promise. Compugen

The EMA validated the MAA for the Gilead Investigational CAR T Product for MCL Kite, a Gilead (GILD) company, announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) of the investigational CAR T product KTE-X19 for adult patients with relapsed or refractory mantle cell lymphoma (MCL

Coronavirus On January 7, 2020, a novel coronavirus (2019-nCoV) was identified in humans in Wuhan City, Hubei Province, China. Additional cases have been found in the United States and in a growing number of countries around the world.    Coronaviruses are a family of viruses that can lead to respiratory illness, including Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). Coronaviruses are …

A Comprehensive Essay Part 3 In parts 1 and 2 of this comprehensive essay Vertex (VRTX) was the firm we used as a case in point to demonstrate successful criteria and strategies towards evaluating biotech firms. As a matter of fact, we use the histories of real firms in this essay for the sake of demonstrating the above without considering the Companies . . . …

In the NEWS: Coronavirus Yesterday the CDC announced the first US case of coronavirus which has killed 17 and sickened hundreds of people in China. According to officials the first US case is of a very healthy 30 year old male currently being isolated at a medical center outside Seattle, WA so as not to pose a threat of contamination to the public. The CDC …

Forty Seven On December 21, 2018 Prohost picked Forty Seven (FTSV) at $16.95 adding it to its Portfolio of biotech firms with solid scientific and non-scientific fundamentals. Forty Seven develops novel checkpoint therapies to activate macrophages in the fight against cancer. The firm targets the CD47 pathway to engage macrophages in fighting tumors.  Macrophages function as . . . This content is for paid subscribers. …

Outperforming Prohost Picks  January 16, 2020 at 11:30 am EST MRNA Trading at $21.35 UP $1.01 AMGN Trading at $243.50 UP $1.80 FTSV  Trading at $40.00 UP $3.20 RETA Trading at $217.01 UP $4.56 ALNY Trading at $119.26 UP $1.17 CGEN Trading at $5.96 UP $0.17 PTCT  Trading . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Nektar in the NEWS The FDA's Anesthetic and Analgesic Advisory Committee (AADPAC) and Drug Safety and Risk Management Advisory Committee (DSaRM) unanimously voted no regarding the approval of Nektar Pharmaceuticals’ (NKTR) New Drug Application (NDA) for its opioid product oxycodegol (formerly NKTR-181). In a short

A Comprehensive Essay Part 2 In Part 1 of our comprehensive essay series Vertex Pharmaceuticals (VRTX) was the first firm we used to make a case in point to demonstrate successful criteria and strategies towards evaluating biotech firms. In Part 2, Vertex . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

XBiotech XBiotech (XBIT), headquartered in Austin, Texas, develops innovative proprietary manufacturing technology that reduces the cost and complexity of biological drug production. XBiotech is dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies. The firm is currently advancing a pipeline of therapies by harnessing naturally occurring antibodies from patients with immunity to certain diseases. Indeed, XBiotech is utilizing natural human immunity . . . This content …

Nektar Therapeutics and Bristol-Myers Squibb Agreement Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) announced their agreement for a new joint development plan aimed at advancing the combination of Nektar’s bempegaldesleukin (bempeg) + Bristol-Myers’ Opdivo (nivolumab) into multiple new registrational trials. The decision is based on a revision of the strategic collaboration agreement. It includes a new plan where both firms will expand the active clinical development …

Moderna's mRNA Vaccine Today could be one of the important early days as Moderna (MRNA) succeeded in cementing proof of concept for the validity of its messenger RNA (mRNA) as a vaccine. Moderna announced yesterday positive seven-month interim safety and immunogenicity data after the third and final vaccination in the Phase 1 study of its investigational cytomegalovirus (CMV . . . This content is for …

A Comprehensive Essay Part 1 Yes, we have stories to tell about some of our picked stocks which proved to be highly successful after being condemned by erroneous evaluations from unfair analysts. Some of these firms faced problems that are not unusual for drug designing and developing firms. While trying to overcome their obstacles, the firms in question were faced with unfortunate debilitating attacks by …

Coming Soon at Prohost Biotech We have stories to tell about our picked stocks which we believe could deepen the Prohost Biotech readers’ understanding of our strategy regarding the evaluation of the biotech companies. Our strategy has made it possible for us to fairly evaluate both the development-stage firms and the revenues- and incomes-generating firms in the biotech sector.     Most of our stories will …

Prohost Letter #438 End of the Year Issue  2019 Happy New Year 2020 The NASDAQ reached 9000 for the first time in the market history on December 30, 2019. However, on the last trading day of 2019, the Nasdaq Composite Index closed at 8,945.99 after giving back 60.62 points or 0.7%. During the departed year, however, the stock exchange was boosted by the outperformance of …